Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1042)	5/2/2000 7:49:00 PM
From: rkrw	Read Replies (1) \| Respond to of 52153

<<One recent apparently adverse development for them was the recent decision by the GENZ/Pharming joint venture on Pompe's disease to license a traditional, non-Pharming, production method. I don't know if this was a Pharming-specific problem, or a problem with the whole concept (which would be bad for GZTC as well, of course).>> GZTC is focusing on mab production. The Pharming product isn't a mab. BTW, today's deal was with abgx. A key for GZTC will be getting some of these partnered antibodies into the clinic.